|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01XX11
|
|
gptkbp:CASNumber
|
856866-72-3
|
|
gptkbp:chemicalFormula
|
C17H15FN6O3
|
|
gptkbp:drugClass
|
gptkb:oxazolidinone
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
powder for solution for infusion
|
|
gptkbp:genericName
|
gptkb:tedizolid
|
|
gptkbp:indication
|
Gram-positive bacterial infections
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:manufacturer
|
gptkb:Merck_&_Co.
|
|
gptkbp:mechanismOfAction
|
protein synthesis inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notEffectiveAgainst
|
Gram-negative bacteria
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:proteinBinding
|
70-90%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
dizziness
headache
|
|
gptkbp:synonym
|
gptkb:tedizolid_phosphate
|
|
gptkbp:usedFor
|
acute bacterial skin and skin structure infections
bacterial skin infections
|
|
gptkbp:bfsParent
|
gptkb:Bausch_Health_Companies_Inc.
gptkb:MRK
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sivextro
|